BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34668265)

  • 1. Comparison of myeloid neoplasms with nonclassic 3q26.2/MECOM versus classic inv(3)/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation.
    Gao J; Gurbuxani S; Zak T; Kocherginsky M; Ji P; Wehbe F; Chen Q; Chen YH; Lu X; Jennings L; Frankfurt O; Altman J; Sukhanova M
    Genes Chromosomes Cancer; 2022 Feb; 61(2):71-80. PubMed ID: 34668265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
    Ottema S; Mulet-Lazaro R; Beverloo HB; Erpelinck C; van Herk S; van der Helm R; Havermans M; Grob T; Valk PJM; Bindels E; Haferlach T; Haferlach C; Smeenk L; Delwel R
    Blood; 2020 Jul; 136(2):224-234. PubMed ID: 32219447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
    Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
    Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities.
    Baldazzi C; Luatti S; Zuffa E; Papayannidis C; Ottaviani E; Marzocchi G; Ameli G; Bardi MA; Bonaldi L; Paolini R; Gurrieri C; Rigolin GM; Cuneo A; Martinelli G; Cavo M; Testoni N
    Genes Chromosomes Cancer; 2016 Apr; 55(4):375-88. PubMed ID: 26815134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
    Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
    Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3q26.2/
    Tang Z; Wang W; Yang S; El Achi H; Fang H; Nahmod KA; Toruner GA; Xu J; Thakral B; Ayoub E; Issa GC; Yin CC; You MJ; Miranda RN; Khoury JD; Medeiros LJ; Tang G
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672407
    [No Abstract]   [Full Text] [Related]  

  • 7. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
    Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. t(3;8)(q26.2;q24) Often Leads to MECOM/MYC Rearrangement and Is Commonly Associated with Therapy-Related Myeloid Neoplasms and/or Disease Progression.
    Tang G; Hu S; Wang SA; Xie W; Lin P; Xu J; Toruner G; Zhao M; Gu J; Doty M; Li S; Medeiros LJ; Tang Z
    J Mol Diagn; 2019 Mar; 21(2):343-351. PubMed ID: 30576868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
    Wang HY; Rashidi HH
    Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a dual-color, double fusion FISH assay to detect RPN1/EVI1 gene fusion associated with inv(3), t(3;3), and ins(3;3) in patients with myelodysplasia and acute myeloid leukemia.
    Shearer BM; Sukov WR; Flynn HC; Knudson RA; Ketterling RP
    Am J Hematol; 2010 Aug; 85(8):569-74. PubMed ID: 20556821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
    Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
    Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and Genomic Profiles of Korean Patients with
    Lee J; Kim SM; Kim S; Yun J; Jeong D; Lee YE; Roh EY; Lee DS
    Ann Lab Med; 2022 Sep; 42(5):590-596. PubMed ID: 35470277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular approaches identify a cryptic MECOM rearrangement in a child with a rapidly progressive myeloid neoplasm.
    Capela de Matos RR; Othman MAK; Ferreira GM; Costa ES; Melo JB; Carreira IM; de Souza MT; Lopes BA; Emerenciano M; Land MGP; Liehr T; Ribeiro RC; Silva MLM
    Cancer Genet; 2018 Feb; 221():25-30. PubMed ID: 29405993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations.
    Tang Z; Tang G; Hu S; Patel KP; Yin CC; Wang W; Lin P; Toruner GA; Ok CY; Gu J; Lu X; Khoury JD; Medeiros LJ
    Cancer Genet; 2019 Apr; 233-234():21-31. PubMed ID: 31109591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MECOM: A Very Interesting Gene Involved also in Lymphoid Malignancies.
    Liu K; Tirado CA
    J Assoc Genet Technol; 2019; 45(3):109-114. PubMed ID: 31554743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two effects of GATA2 enhancer repositioning by 3q chromosomal rearrangements.
    Suzuki M; Katayama S; Yamamoto M
    IUBMB Life; 2020 Jan; 72(1):159-169. PubMed ID: 31820561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. H2AFY is a novel fusion partner of MECOM in acute myeloid leukemia.
    Han Q; Lu J; Wang J; Ye J; Jiang X; Chen H; Liu C; Chen L; Lin T; Chen S; Sun M; Gao F
    Cancer Genet; 2018 Apr; 222-223():9-12. PubMed ID: 29666008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis.
    Yamaoka A; Suzuki M; Katayama S; Orihara D; Engel JD; Yamamoto M
    Blood Adv; 2020 Apr; 4(8):1722-1736. PubMed ID: 32330245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements.
    Lahortiga I; Vázquez I; Agirre X; Larrayoz MJ; Vizmanos JL; Gozzetti A; Calasanz MJ; Odero MD
    Genes Chromosomes Cancer; 2004 Jul; 40(3):179-89. PubMed ID: 15138998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MECOM rearrangement involving the MYC locus: Two additional patients with the rare translocation, t(3;8)(q26.2;q24), and molecular review.
    Smith SC; Qdaisat TZS; Althof PA; Dave BJ; Sanmann JN
    Leuk Res; 2020 Aug; 95():106387. PubMed ID: 32535247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.